Breaking Finance News

QuintilesIMS (NYSE:Q) target price raised to $94.00, issued a report today by Goldman Sachs

QuintilesIMS (NYSE:Q) had its target price raised to $94.00 by Goldman Sachs in a report released Wednesday October 05, 2016. The new target price indicates a possible upside of 0.19% based on the company's last stock close price.

Yesterday QuintilesIMS (NYSE:Q) traded 1.90% higher at $78.79. The company’s 50-day moving average is $77.50 and its 200-day moving average is $71.10. The last stock close price is up 12.92% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 157,576 shares of the stock were exchanged, down from an average trading volume of 1,104,280

See Chart Below

QuintilesIMS (NYSE:Q)

QuintilesIMS has a 52 week low of $55.01 and a 52 week high of $81.26 with a P/E ratio of 24.14 The company’s market cap is currently $0.

In addition to Goldman Sachs reporting its stock price target, a total of 15 brokers have issued a research note on the company. The average stock price target is $76.50 with 8 brokers rating the stock a strong buy, 9 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About QuintilesIMS (NYSE:Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. The Company's segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Product Development segment consists of clinical solutions and services, and advisory services. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.